CLVS, Roche ink clinical-trial collaboration for Atezolizumab (PD-L1) + Rociletinib in EGFR-mutant NSCLC: http://finance.yahoo.com/news/clovis-oncology-enters-clinical-trial-123000743.html Yet another collaboration in which no cash in changing hands.